Propranolol (capsule): Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Propranolol}} | {{Propranolol}} | ||
{{CMG}} | {{CMG}} | ||
'''''For patient information, click <u>[[Propranolol (patient information)|here]]'''''</u> | '''''For patient information about Propranolol, click <u>[[Propranolol (patient information)|here]].'''''</u> | ||
{{SB}} Inderal LA<sup>®</sup>, InnoPran XL<sup>®</sup> | {{SB}} Inderal LA<sup>®</sup>, InnoPran XL<sup>®</sup> |
Revision as of 21:59, 9 February 2014
Propranolol |
---|
Inderal LA® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Clinical Trials on Propranolol |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information about Propranolol, click here.
Synonyms / Brand Names: Inderal LA®, InnoPran XL®
Overview
Category
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages